Skip to main content
    M

    Mersana Therapeutics Inc (MRSN)

    Official site

    BIOTECHNOLOGY

    $29.08
    +0.00 (+0.00%)

    Last updated: Jan 06, 2026 at 4:00 PM ET

    Mersana Therapeutics Inc (MRSN) Financials: Revenue, Profit and Cash Flow

    Updated Nov 14, 2025. Financial statements from company filings, amounts in US dollars.

    Mersana Therapeutics reported revenue of $40.50M for the fiscal year ended Dec 31, 2024, up 9.9% from the year before. That year, net income was -$69.19M with a net margin of -170.9%, operating cash flow was -$82.34M and free cash flow was -$82.47M. The quarter ended Sep 30, 2025 had revenue of $11.01M and net income of -$7.54M.

    Revenue and Margins

    Over the 9 years to Dec 2024, revenue grew from $10.36M, a compound annual rate of 16.4%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2024$40.50M+9.9%100.0%-181.1%-170.9%
    Dec 2023$36.85M+38.7%100.0%-487.5%-465.8%
    Dec 2022$26.58M+61716.3%100.0%-766.6%-768.3%
    Dec 2021$43.00K-94.8%100.0%-392693.0%-395488.4%
    Dec 2020$828.00K-98.0%100.0%-10641.3%-10633.5%
    Dec 2019$42.12M+297.6%100.0%-71.7%-67.0%
    Dec 2018$10.59M-39.6%100.0%-619.7%-606.5%
    Dec 2017$17.55M-30.3%100.0%-225.8%-220.6%
    Dec 2016$25.17M+143.0%100.0%-54.9%-54.4%
    Dec 2015$10.36MN/A100.0%-157.7%-158.6%
    Annual, fiscal years ended Dec 2015 to Dec 2024

    Income Statement

    In the fiscal year ended Dec 2024, the net loss narrowed from the year before. In the quarter ended Sep 2025, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Revenue$40.50M$36.85M$26.58M$43.00K$828.00K$42.12M$10.59M$17.55M$25.17M$10.36M
    Gross profit$40.50M$36.85M$26.58M$43.00K$828.00K$42.12M$10.59M$17.55M$25.17M$10.36M
    Research and development$73.02M$148.27M$173.38M$132.01M$67.04M$55.04M$59.91M$46.70M$32.01M$21.35M
    Operating income-$73.34M-$179.67M-$203.77M-$168.86M-$88.11M-$30.20M-$65.66M-$39.62M-$13.82M-$16.34M
    Net income-$69.19M-$171.67M-$204.21M-$170.06M-$88.05M-$28.21M-$64.26M-$38.71M-$13.70M-$16.43M
    EBITDAN/AN/AN/A-$168.00M-$87.19M-$29.18M-$64.69M-$38.98M-$13.17M-$16.13M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Revenue$11.01M$3.06M$2.75M$16.36M$12.60M$2.29M$9.24M$10.70M$7.70M$10.65M$7.80M$14.69M
    Gross profit$11.01M$3.06M$2.75M$16.36M$12.60M$2.29M$9.24M$10.70M$7.70M$10.65M$7.80M$14.69M
    Operating income-$7.67M-$24.52M-$24.51M-$14.81M-$12.07M-$25.45M-$21.00M-$21.43M-$43.94M-$56.50M-$57.80M-$45.83M
    Net income-$7.54M-$24.30M-$24.12M-$14.12M-$11.50M-$24.27M-$19.31M-$19.54M-$41.66M-$54.31M-$56.16M-$44.92M
    Last 12 quarters

    Balance Sheet

    As of Dec 2024, cash and equivalents exceeded total debt of $23.45M by $84.30M. Shareholder equity was negative, at -$9.51M, as total liabilities of $154.17M exceeded total assets of $144.66M.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Total assets$144.66M$226.06M$334.34M$206.11M$273.40M$107.54M$78.50M$130.72M$105.09M$14.41M
    Current assets$136.90M$214.06M$319.22M$188.90M$258.58M$101.33M$70.13M$117.54M$102.17M$12.75M
    Cash and equivalents$107.75M$174.56M$128.88M$177.95M$255.09M$62.35M$59.63M$26.59M$100.30M$11.53M
    Total liabilities$154.17M$189.16M$242.28M$84.37M$45.31M$29.22M$69.71M$60.72M$66.26M$57.10M
    Short-term debt$12.50M$2.08M$0$2.30M$1.53M$667.00KN/AN/AN/AN/A
    Long-term debt$10.95M$23.15M$24.93M$24.63M$4.98M$4.20MN/A$0N/AN/A
    Shareholder equity-$9.51M$36.90M$92.06M$121.74M$228.09M$78.32M$8.79M$69.99M-$55.62M-$42.69M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total assets$62.69M$84.57M$112.47M$144.66M$169.53M$179.13M$198.37M$226.06M$262.90M$311.00M$296.19M$334.34M
    Total liabilities$122.22M$137.72M$143.34M$154.17M$168.48M$170.70M$170.39M$189.16M$210.71M$221.20M$231.90M$242.28M
    Cash and equivalents$56.39M$76.97M$102.29M$107.75M$78.87M$59.00M$75.19M$174.56M$186.28M$128.73M$122.83M$280.71M
    Shareholder equity-$59.54M-$53.15M-$30.87M-$9.51M$1.05M$8.43M$27.98M$36.90M$52.20M$89.80M$64.29M$92.06M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2024.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Operating cash flow-$82.34M-$168.88M-$49.36M-$139.99M-$74.70M-$67.74M-$55.22M-$42.68M$31.59M-$9.64M
    Capital expenditures$132.00K$2.17M$2.20M$648.00K$473.00K$605.00K$1.37M$1.14M$1.08M$619.00K
    Free cash flow-$82.47M-$171.05M-$51.56M-$140.64M-$75.17M-$68.35M-$56.59M-$43.82M$30.50M-$10.26M
    Dividends paidN/A$94.94MN/A$640.00K$561.00K$489.00KN/A$0N/AN/A
    Investing cash flow$11.44M$119.88M-$152.72M-$648.00K$37.03M-$27.29M$87.19M-$99.62M-$1.08M-$783.00K
    Financing cash flow$4.09M$94.67M$153.02M$63.65M$230.41M$97.70M$1.06M$68.60M$58.26M$9.96M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow-$3.19M-$22.60M-$29.33M-$19.25M-$8.58M-$21.86M-$32.66M-$31.96M-$46.08M-$61.83M-$29.00M-$51.23M
    Capital expenditures$0$0$0$0$0$0$132.00K$386.00K$472.00K$399.00K$911.00K$785.00K
    Free cash flow-$3.19M-$22.60M-$29.33M-$19.25M-$8.58M-$21.86M-$32.79M-$32.35M-$46.55M-$62.23M-$29.92M-$52.01M
    Last 12 quarters

    Frequently Asked Questions About MRSN

    What is Mersana Therapeutics' annual revenue?

    Mersana Therapeutics reported revenue of $40.50M for the fiscal year ended Dec 31, 2024.

    How fast is Mersana Therapeutics' revenue growing?

    Revenue was up 9.9% for the fiscal year ended Dec 31, 2024 compared with the year before. The compound annual revenue growth rate over 3 years was 880.2%.

    Is Mersana Therapeutics profitable?

    No. Mersana Therapeutics reported net income of -$69.19M for the fiscal year ended Dec 31, 2024, with a net margin of -170.9%.

    How much free cash flow does MRSN generate?

    For the fiscal year ended Dec 31, 2024, operating cash flow of -$82.34M minus capital expenditures of $132.00K produced free cash flow of -$82.47M.

    How much debt does Mersana Therapeutics have?

    The balance sheet dated Dec 31, 2024 reported long-term debt of $10.95M, short-term debt of $12.50M and cash and equivalents of $107.75M.